The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Predictive biomarkers for RAS-wt mCRC treated with cetuximab and m-FOLFOXIRI
Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, presents findings from a biomarker analysis from the Phase II DEEPER trial (NCT02515734). The trial assessed cetuximab versus bevacizumab with modified (m)-FOLFOXIRI in patients with previously untreated metastatic colorectal (mCRC) with RAS wild-type (wt) tumors. In the cetuximab arm, a higher depth of response was reported in patients with RAS/BRAF wild-type and left-sided tumors. Male patients or people with extra-hepatic metastases may also benefit more from cetuximab with m- FOLFOXIRI. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
